Published Studies
Year | Publication | Categories |
---|---|---|
2023 |
Results from the COMPARE Study – How Do Different Medications Impact IBD Patients?
Summary When IBD patients start taking a new medication, it can be hard to know if it will finally be the medication to help achieve remission, or if the side effects will impact sleep, social life, and ability to work. Over 400 IBD Partners participants took part in the COMPARE study to compare the effects of Entyvio vs. Stelara for Crohn's disease and Entyvio vs. Xeljanz for ulcerative colitis. Our patient partners identified fatigue and pain as outcomes of particular interest for this research to focus on. Keywords COMPARE; Entyvio; Stelara; Xeljanz; vedolizumab; ustekinumab; tofacitinib; patient-reported outcomes; pain; fatigue; comparative effectiveness; Crohn s disease; ulcerative colitis; |
Medications |
2019 |
Changes in Patient-Reported Outcomes With Vedolizumab Therapy in Patients With Inflammatory Bowel Diseases (IBD): Results From the IBD Partners Patient Powered Research Network
Summary We studied whether patients starting Entyvio® (vedolizumab), who had previously used an anti-TNF biologic, such as Remicade® (infliximab) or Humira® (adalimumab), responded differently than people who had not used one of these therapies. We studied 380 patients with Crohn's disease and ulcerative colitis in the IBD Partners cohort who were starting vedolizumab. We found that patients who had not previously used an anti-TNF biologic had higher remission rates and improved quality of life. Full Scientific Manuscript Keywords Entyvio; vedolizumab; anti-TNF biologic; |
Medications |